Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Goodwill (2023 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Goodwill for 3 consecutive years, with $4.7 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Goodwill changed N/A year-over-year to $4.7 million, compared with a TTM value of $4.7 million through Mar 2025, changed N/A, and an annual FY2024 reading of $4.7 million, changed 0.02% over the prior year.
  • Goodwill was $4.7 million for Q1 2025 at Zevra Therapeutics, roughly flat from $4.7 million in the prior quarter.
  • Across five years, Goodwill topped out at $4.7 million in Q4 2024 and bottomed at $4.7 million in Q4 2023.
  • Average Goodwill over 3 years is $4.7 million, with a median of $4.7 million recorded in 2023.
  • Peak annual rise in Goodwill hit 0.02% in 2024, while the deepest fall reached 0.02% in 2024.
  • Year by year, Goodwill stood at $4.7 million in 2023, then grew by 0.02% to $4.7 million in 2024, then fell by 0.02% to $4.7 million in 2025.
  • Business Quant data shows Goodwill for ZVRA at $4.7 million in Q1 2025, $4.7 million in Q4 2024, and $4.7 million in Q4 2023.